European Journal of Cancer: Supplement
Издатель: Elsevier · ISSN 1359-6349 · 9 статей
- Editorial board
- Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
- Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours
- Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study
- Title page
- Disclaimer
- Table of contents
- Isocitrate dehydrogenase mutations as potential tumour agnostic targets
- Clinical advancement in the management of mutant isocitrate dehydrogenase (IDH) cancers